Shots:

• The P-I (CT-996-201) study assesses SAD & MAD of CT-996 vs PBO in otherwise-healthy adults, with part 1 involving 40 obese subjects (completed), part 2 involving 25 obese subjects without T2D (completed) & part 3 involving 30 obese subjects with T2D (anticipated in Q4’24)
• Topline data from the 2 arms depicted a mean weight loss of -6.1% among obese individuals without T2D in 4wks. while a weight loss of -7.3% vs -1.2% was observed post 4wks. with PK data suggesting QD oral dosing
• Safety was well-tolerated, aligned with incretin drugs & did not lead to treatment discontinuations; blood levels of CT-996 were stable regardless of fasting or high-fat meals. It will advance to P-II based on these results

Ref: Roche | Image: Roche

Related News:- Roche’s Accu-Chek SmartGuide CGM System Gains CE Mark for Diabetic Patients

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com